• LAST PRICE
    0.0990
  • TODAY'S CHANGE (%)
    Trending Up0.0615 (164.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0300 / 0.0375
  • Day Range
    Low 0.0251
    High 0.0995
  • 52 Week Range
    Low 0.0010
    High 0.4190
  • Volume
    577,229
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.0375
TimeVolumeSRNEQ
09:32 ET91180.03
09:35 ET2540.03
09:37 ET5000.03
09:44 ET1100.03
09:53 ET28000.03
10:18 ET7660.03
10:20 ET8590.03
10:22 ET10200.03
11:02 ET1540.03
11:12 ET2270.03
11:14 ET13540.03
11:21 ET88560.03
11:45 ET21000.0385
11:52 ET30000.03
12:03 ET10000.03
12:37 ET10000.03
12:55 ET17600.03
01:29 ET707820.04
01:45 ET10000.026
02:12 ET1000.0266
02:21 ET7160.0266
02:27 ET85000.0269
02:48 ET22000.0269
02:52 ET2000.0269
03:06 ET1000.0269
03:15 ET94150.0269
03:17 ET1030.026
03:28 ET3000.0251
03:42 ET38580.0251
04:00 ET4441040.099
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSRNEQ
Sorrento Therapeutics Inc
20.7M
-0.1x
---
United StatesRDHL
Redhill Biopharma Ltd
16.0M
-0.1x
---
United StatesCNTG
Centogene NV
23.7M
-0.6x
---
United StatesBIOQ
Bioqual Inc
64.4M
-140.7x
-25.28%
United StatesCDTX
Cidara Therapeutics Inc
62.5M
-1.8x
---
United StatesPSNL
Personalis Inc
61.3M
-0.5x
---
As of 2024-02-24

Company Information

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

Contact Information

Headquarters
4955 Directors PlaceSAN DIEGO, CA, United States 92121
Phone
858-203-4100
Fax
858-203-4028

Executives

Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
Henry Ji
Lead Independent Director
Dorman Followwill
Director
Kim Janda
Director
Jaisim Shah
Independent Director
David Lemus

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$20.7M
Revenue (TTM)
$64.3M
Shares Outstanding
551.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.48
EPS
$-1.09
Book Value
$-0.04
P/E Ratio
-0.1x
Price/Sales (TTM)
0.3
Price/Cash Flow (TTM)
---
Operating Margin
-734.68%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.